Cancer statistics, 2026
2026/01/01 by Rebecca L. Siegel, Tyler B. Kratzer, Nikita Sandeep Wagle +2 · 1 voice · 29 citations
Biochemistry, Genetics and Molecular Biology · Economics, Econometrics and Finance · Medicine · #COVID-19 and healthcare impacts #Cancer Genomics and Diagnostics #Economic and Financial Impacts of Cancer
paper · doi:10.3322/caac.70043
openalex publication_date 2026/01/01 · openalex created_date 2026/01/14 · openalex updated_date 2026/07/31
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5-year relative survival, which reached a milestone 70% for diagnoses during 2015-2021 overall, 69% for regional-stage disease, and 35% for distant-stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid-1990s. People with high-mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life-saving cancer treatment.
Citations
Cited by
- Therapeutic targeting of the eIF4E cap-binding domain reveals control of lineage fate in prostate cancer
- Colorectal cancer statistics, 2026
- Chromosomal instability induced by CRISPR/Cas9: implications for pancreatic cancer therapy
- Cancer statistics, 2026: Charting a course for a national cancer research agenda
- Cancer statistics, 2026: Charting a course for a national cancer research agenda. [europepmc]
- Tissue-Derived Extracellular Vesicles Define Diagnostic Biomarkers for Renal Cell Carcinoma. [europepmc]
- Colorectal cancer statistics, 2026. [europepmc]
- Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances. [europepmc]
- HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape. [europepmc]
- Interleukin-18 as a Potential Biomarker for Radiotherapy-Related Pain in Breast Cancer: Implications for Personalized Pain Management. [europepmc]
- Resveratrol as a Modulator of Adriamycin-, Taxol-, and Cisplatin-Induced Cytotoxicity in MCF-7 Breast Cancer Cells. [europepmc]
- Sex differences in gene regulation and its impact on cancer incidence. [europepmc]
- Hypoxia-Induced Fibroblast IL-6 Promotes Immunosuppressive Macrophage Phenotypes in Pancreatic Cancer. [europepmc]
- Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. [europepmc]
- Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials: A Systematic Review. [europepmc]
- Exploring current cancer screening practices and guidelines for adults under age 50 in the United States. [europepmc]
- Intratumoral Microbiota in Tumor: Current Understandings and Future Perspectives. [europepmc]
- Multi-Task and Federated Learning for Breast and Lung Cancer Screening and Diagnosis: A Survey and Future Research Directions. [europepmc]
- PARK2-Mediated PGK1 Degradation Suppresses Partial Epithelial-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer. [europepmc]
- Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies. [europepmc]
- CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor [europepmc]
- Osteopathic Manipulative Treatment as a Complementary and Integrative Approach for Cancer Supportive Care: A Systematic Review [europepmc]
- Revisiting the Lipid–Cancer Axis: PCSK9, ANGPTL3, and CETP as Emerging Biomarkers and Therapeutic Targets in Oncology [europepmc]
- MMPs’ Impact on Carcinogenesis in Specific Organs and Systems [europepmc]
- Small Molecule Liver X Receptor Modulator GAC0001E5 Targets Mechanisms of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer Cells [europepmc]
- Clinical and Sociodemographic Determinants of Treatment Selection in Prostate Cancer: A Population-Based Study in the United States (2004–2022) [europepmc]
- Impact of Hashimoto Thyroiditis on Long-Term Outcomes in Differentiated Thyroid Carcinoma [europepmc]
- SAVE: Spectrum-Aided Visual Enhancement for AI-Based Skin Cancer Detection [europepmc]
- Predicting Response to Immune Checkpoint Inhibitors in Melanoma: Emerging Approaches in Digital Pathology, Spatial Profiling and Machine Learning [europepmc]
Discussions
Related